Background. Postmenopausal estrogen replacement therapy has been associated with favorable levels of cardiovascular disease risk factors, but these associations and the relations between estrogen use and subclinical disease have not been examined in large samples of older women.
De espite the relatively low rates of cardiovascular disease among premenopausal women, cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women, with associated medical care costs exceeding $11 billion per year. ' The increase in heart disease risk after menopause has been suggested to result from unfavorable changes in lipid profiles associated with relative lack of estrogen.2 Postmenopausal estrogen replacement has been suggested as a useful preventive therapy,
The Cardiovascular Health Study (CHS) is a prospective, observational, epidemiological study of risk factors for coronary heart disease and stroke in 5201 men and women .65 years old. It includes a large, multicenter sample of older women undergoing systematic determination of subclinical disease, with concurrent measurements of coagulation factors and indicators of medication compliance. Data from the baseline examination were analyzed (1) to describe the frequency and duration of estrogen use in a multicenter sample of older women; (2) to examine associations of past and present estrogen use with demographic factors, cardiovascular disease risk factors, subclinical disease, and prevalent disease; and (3) to determine the independence of associations between estrogen use and subclinical disease as measured by ECG left ventricular (LV) mass, carotid arterial wall thicknesses, and carotid stenosis.
Methods CHS participants were recruited from a random sample of the Health Care Financing Administration Medicare eligibility lists in four US communities: Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh (Allegheny County), Pennsylvania. Potential participants were excluded if they were institutionalized, wheelchair-bound in the home, expecting to move from the Field Center area in the next 3 years, or undergoing radiation or chemotherapy for cancer. The sample included 2955 women 65 to 100 years old, with a mean age of 72.4 years. Details of design and methods have been published. 15 Eligible subjects who gave informed consent answered standard questionnaires on personal habits, reproductive history, and medical history (including hospitalizations, diagnoses, and cardiac procedures). Cognitive function was measured by the Mini-Mental state examination' and physical activity with a modified Minnesota leisure time questionnaires Prescription medication use in the preceding 2 weeks was collected directly from prescription bottles,18 including the number of doses prescribed in the past 2 weeks. The number of doses taken in the preceding 2 weeks was reported by the participant. Use of nonprescription drugs such as aspirin, calcium supplements, and fish-oil preparations was ascertained by questionnaire. In addition to current medications, women were asked whether they had ever used estrogens or other hormones for menopausal symptoms and the duration of use. Reported duration was available in 61% of past users and 80% of present users.
Blood pressure was measured in the right arm of seated subjects after a 5-minute rest using a randomzero sphygmomanometer. The average of two measurements was used for analysis. Duplicate measurements of supine blood pressure in both arms and both ankles were taken with a standard mercury sphygmomanometer and an 8-MHz Doppler probe. A low ratio of these measures (the ankle-arm index) was used as a measure of arterial occlusive disease in the lower extremities.
Anthropometric measurements included weight, height, and waist and hip circumferences. Bioelectric impedance was used as an estimate of body fat; the bioresistance estimate from this measurement was used as an estimate of lean body mass. Twelve-lead, resting
ECGs were obtained on all participants, and abnormalities were defined by the Minnesota code. '9 Venipuncture was performed early in the clinic visit after a 12-hour fast. Multiple aliquots of plasma were prepared, frozen at -700C, and shipped weekly on dry ice to a central laboratory. Fasting serum chemistry analyses included measurement of potassium, creatinine, uric acid, albumin, and glucose. Serum insulin was measured by radioimmunoassay according to the method of Herbert 
Results
Of 2955 women interviewed, 356 (12%) were currently using oral estrogen or combined estrogen/progesterone. Two hundred eighty-one (79%) of these women were taking unopposed estrogen. An additional 784 women (26.5%) reported past use of hormones but did not have current prescriptions, making a total of 39% of women who were ever users of postmenopausal estrogens. Estrogen use was more common in younger women and in those with prior hysterectomy for both present and past use (Fig 1) . Median duration of use was 18 years in present users compared with 3 years in past users (P<.0001, Fig 2) . Estrogen Use Versus Nonuse Estrogen users (past or present) were younger and more highly educated and had higher incomes than nonusers (Table 1) t"Present/past/never" indicates three-way comparison adjusted for age using ANCOVA for continuous variables and X 2 (two df) on age-adjusted proportions for dichotomous variables. Denominators for some variables may vary because of missing data. *Not adjusted for age. §Adjusted for age and standing height. IlAdjusted for age and mitral early peak flow velocity. A similar model of maximum internal carotid thickness showed significant associations for ever versus never, present versus past, and present versus never use after adjustment for age, hysterectomy, smoking, alcohol intake, lipid-lowering medications, diabetes, waist circumference, and fibrinogen and albumin levels. The magnitude of these associations was greater than that for common carotid thickness, with ever users having approximately 0.08 mm thinner internal carotid walls than never users. Addition of lipids to this model effectively removed these associations. Duration of use was not associated with internal or common carotid thickness in these multivariate models.
Estrogen use was associated with 3.6 g lower ECG LV mass in comparing ever with never users after adjustment for age, hysterectomy, education, past smoking, definite CHD (in models including women with prevalent CHD), and insulin and glucose levels. Addition of lipids to this model tended to increase the magnitude of these associations, and exclusion of women with prevalent CHD tended to reduce them. Duration of use was not associated with LV mass in these multivariate models. Multiple logistic regression of carotid stenosis did not demonstrate independent associations with estrogen use.
Discussion Past or present estrogen use was strongly associated with favorable risk factor profiles, including lower levels of LDL cholesterol, fibrinogen, glucose, insulin, obesity, and age; higher levels of HDL cholesterol and socioeconomic status (as measured by age and education); and increased medical care utilization as measured by vaccination. Past or present estrogen users (ever users) also had lower levels of subclinical disease as measured by carotid intimal-medial thickness or stenosis, ECG LV mass, and Doppler A/E ratio, as well as lower prevalence of chronic obstructive pulmonary disease. Although present estrogen use was associated with thinner carotid intimal-medial thickness after adjustment for covariates other than lipid levels, after inclusion of lipids the associations with common carotid thickness and ECG LV mass were of borderline significance in ever versus never users and generally were not significant for other comparisons.
Prevalence Compared With Other Studies
Present estrogen use was reported by 12% of women in CHS, considerably lower than the 22% to 35% prevalences previously reported.3,5.6,8'9,28 Part of this difference may be a result of the older age of the CHS sample,8'9 since prevalence of present estrogen use was 17 .3% in a cohort of women of similar age.29 Differences between the present study and earlier studies may also be caused by secular trends, since estrogen use declined in the late 1970s after reports of increased risk of endometrial cancer. 30 Geographic patterns may also be a factor, since the Sacramento subsample in CHS showed usage patterns more like those reported by other California studies.5'8'29 The high prevalence of unopposed estrogen use may reflect carryover of prescribing practices in women placed on estrogens many years before but was identical to that reported by Barrett Estrogen use has not been strongly related to hemostatic factors, although the lack of information in this area has been cited previously.33 Lower fibrinogen levels and higher levels of factor VII have been reported after oral estrogen therapy in 18 postmenopausal women, although the differences observed were not significant.34 Available data are conflicting, however, since other investigators have reported declines in factor VII activity after estrogen therapy without a change in fibrinogen. 35 The large sample size in CHS may provide more stability to estimates of these cross-sectional associations, but interventional studies are needed to assess the true effects of estrogen on hemostatic factors.
Past users formed an interesting "intermediate" group of women, often having risk factor levels between those of present and never users. Study of past users may shed some light on social class and medical care utilization as confounders of estrogen-risk factor relation, since past users are likely to have socioeconomic status and access to care similar to those of present users. That laboratory values among past users were so much more like nonusers than present users suggests that present use, rather than sociodemographics, may be the more important factor in these associations.
Stratification by age showed similar relations between estrogen use and many cardiovascular disease risk factors, suggesting that associations between estrogen use and favorable risk factor profiles are sustained well into the eighth decade of life. The lack of associations with duration of use probably reflected the unreliability of the duration data, which depended on recall of sometimes distant events and which were missing in a large proportion of estrogen users.
Stratification by smoking status showed very few differences in risk factor or subclinical disease associations with estrogen use in ever and never smokers.
Criqui et al1 reported a puzzling interaction between estrogen use and smoking status such that estrogen use was protective against cardiovascular mortality in present and never smokers but associated with increased risk in past smokers. These authors concluded that they ". . . find no evidence to support the alternative hypothesis that postmenopausal estrogen use is somehow selectively dangerous in past smokers."5 In the present study, present and past smokers were analyzed together because the great majority were past smokers and because a selective effect on past smokers appears to be biologically implausible. Examination of possible interactions between past smoking, estrogen use, and mortality must await longitudinal analysis of this group of women. Analyses stratified by medication compliance were performed to examine the hypothesis that estrogen users represent a highly compliant group with decreased cardiovascular risk regardless of estrogen use. 33 To the extent that increased compliance is associated with increased health awareness and in turn with improved cardiovascular disease risk profiles, high levels of compliance in estrogen users and nonusers might be expected to diminish an association between estrogen and risk factors if this association is primarily a result of healthy behavior alone. Although the poor compliance group was small, exclusion of these women demonstrated relations with estrogen use that were almost identical to those in the group as a whole, suggesting that high compliance as measured in this study was not a major confounder of the estrogen-cardiovascular risk relation.
Associations With Subclinical Disease
The use of multiple noninvasive measures of subclinical disease in CHS provided a unique opportunity to examine associations of estrogen use and early cardiovascular disease independent of any diagnosis or detection biases related to estrogen use. The lower levels of internal and common carotid wall thicknesses and ECG LV mass in estrogen users were largely but not entirely explained by risk factor differences, as confirmed by multivariate models. Excluding lipid levels from these models demonstrated strong relations between present estrogen use and carotid wall thicknesses independent of other nonlipid factors. If 25% to 50% of the beneficial effects of estrogen on CHD risk is related to changes in lipid levels, as has been estimated,33 adjustment for lipids might substantially underestimate even cross-sectional relations with subclinical disease measures. 36 This may be particularly true for carotid wall thickness, which is known to be related to lipid levels.37,38
Adjusted differences in common and internal carotid thicknesses were greater in present users than past users compared with never users. This is not surprising, given the considerable difference in duration of use between present and past users, although duration was not significantly associated with wall thickness in multivariate models. It is also of interest that associations with present use were substantially diminished after adjustment for lipids, whereas associations with past use were minimally affected. Differences in wall thicknesses were, with one exception, also greater between present and past users than between past and never users. Had past users been closer to present users in regard to wall thicknesses, one might have inferred that factors other than duration or recentness of use, such as demographics, were somehow underlying this relation. The fact that past users differed little from never users suggests that present use or the factors associated with it are more strongly related to wall thickness than are past use and factors that accompany it.
The finding that associations with LV mass were, if anything, slightly strengthened by adjustment for lipids is intriguing and suggests that lipids are somehow negatively confounding this association. We are unaware of any evidence of a relation between adverse lipid profiles and lower LV mass and would have expected to find just the opposite, given the strong associations of both with obesity. Alternatively, lipids may be related to some unknown factor associated with both estrogen use and lower LV mass, but at present, the weak enhancement of this association defies explanation. The small differences between present and past users in LV mass compared with those between ever users or past users and never users suggests that factors related to ever use, such as demographics, may be more important in the relation of estrogen use to LV mass than currentness of use may be.
Summary
Postmenopausal estrogen use in this sample of older women was associated with favorable risk factor profiles that are similar to those reported in younger women who use estrogen. Estrogen use was also associated with lower levels of subclinical disease, although much of this relation is accounted for by risk factor differences. These findings suggest that postmenopausal estrogen use may be associated with lower risk of cardiovascular disease in women well into the eighth decade of life.
